Gilead Plunges 2.7% as Biotech Sector Falters on Genetic Innovation Hype and Options Action Heats Up

Summary
• Gilead Sciences (GILD) is down 2.74% at $140.45, breaking through the 30-day support level of $145.03.
• The stock is trading at its intraday low of $139.23 after opening at $143.16.
• Sector leader Amgen (AMGN) also down 2.74%, mirroring GILD’s performance.

Biotech is in a tailspin as Gilead Sciences and its peers fall under pressure following a wave of genetic and AI-driven medicine news. With GILD trading at a 7% discount from its 52-week high, options traders are aggressively moving into bearish positions, suggesting a volatile near-term outlook as earnings expectations and sector dynamics shift.

Bearish Momentum Accelerates as Technicals Deter and Short-Term Volatility Grows
Gilead's sharp intraday decline is fueled by a bearish crossover in its short-term technicals and a broader sector selloff. The RSI has fallen to 44.71, signaling weakening momentum, while the MACD histogram shows a deep negative divergence, indicating a widening bearish trend. Meanwhile, the stock is trading below its 30-day moving average of $148.56 and is dangerously close to its 200-day line of $122.56. The move is not necessarily tied to direct news from Gilead, but instead reflects broader sector dynamics and investor caution amid a flurry of biotech advancements and regulatory expectations.

Biotech Sector in Retreat as AMGN and Peers Deter Investors
The broader biotech sector is under pressure, with Amgen (AMGN) also suffering a -2.74% intraday hit, closely mirroring Gilead's move. This synchronized decline suggests a sector-wide re-evaluation rather than a company-specific event. Recent news from MIT and academic journals on AI-driven protein design, gene splicing, and novel drug delivery systems has created a wave of innovation optimism—but also raised questions about competitive positioning and valuation sustainability for large-cap players like Gilead and Amgen. As biotech investors digest these developments, capital is shifting to more speculative or emerging names, leaving mid-to-large caps in a short-term slump.

Bear Call Spreads and Short Dated Puts Take Center Stage as GILD Hits Key Resistance
• 200D MA: $122.56 (well below current price)
• RSI: 44.71 (below neutral, bearish bias)
• MACD: 0.486 / Signal: 1.445 / Histogram: -0.958 (negative divergence)
• Bollinger Bands: 152.73 / 147.44 / 142.14 (GILD near lower band)
• 30D Support: $145.03–145.28
• 200D Support: $117.898–118.896

With GILD near its 30-day support and the RSI indicating weakening momentum, the technical outlook remains bearish in the short to mid-term. Given the high volatility and bearish sentiment, traders may consider short-dated bear call spreads or naked put positions for short-side exposure. The stock is now within a volatile trading range and could test its 200-day support if the downward trend continues. However, the long-term trend is still bullish given its 52-week high of $157.29 and robust fundamentals. That said, the next few sessions will be critical for sentiment, and the options chain is already showing aggressive bearish positioning.

• GILD20260327P140 (Put, $140 strike, 2026-03-27 exp):
- Implied Volatility: 32.76% (moderate)
- LVR: 55.27% (attractive)
- Delta: -0.435 (in 0.3–0.6 range, moderate sensitivity)
- Gamma: 0.051 (reactive to price moves)
- Theta: -0.016 (moderate time decay)
- Turnover: 51,110 (high liquidity)
- Price Change: 86.13% (significant movement)
This put is a strong short-term bearish play due to its high liquidity, moderate delta, and attractive leverage ratio. If GILD falls another 5% to $133.43, the payoff for this put would be $6.57 per contract, yielding a potential 118% return.

• GILD20260327P139 (Put, $139 strike, 2026-03-27 exp):
- Implied Volatility: 28.14% (reasonable)
- LVR: 82.43% (high)
- Delta: -0.369 (in 0.3–0.6 range, sensitive)
- Gamma: 0.057 (reactive to price moves)
- Theta: -0.012 (moderate time decay)
- Turnover: 5,027 (good liquidity)
- Price Change: 35.71% (active movement)
This put stands out for its high leverage and moderate delta, making it ideal for a short-term bearish trade. A 5% drop in GILD would give this put a $9.57 payoff per contract—over a 160% return—making it a top pick for aggressive short-side positioning.

Aggressive bears should consider GILD20260327P139 and GILD20260327P140 as key plays if the stock continues its near-term downward trend. If $140 breaks decisively, the 27th expiration date offers high volatility and strong bearish momentum in the options chain.

Backtest Gilead Sciences Stock Performance
The backtest of GILD's performance after a -3% intraday plunge from 2022 to the present reveals favorable short-to-medium-term gains. The 3-Day win rate is 50%, the 10-Day win rate is 56.02%, and the 30-Day win rate is 59.84%, indicating a higher probability of positive returns in the immediate aftermath of the plunge. The maximum return during the backtest was 5.20%, which occurred on day 59, suggesting that while there is some volatility, GILD can exhibit strong recovery and growth in the following weeks.

Biotech Sector Falters, Gilead Under Pressure: Time to Act on Short-Side Exposure
The current bearish momentum in Gilead and the broader biotech sector signals a key inflection point for short-term traders. As the stock trades near critical support levels and the options market reflects aggressive bearish positioning, the near-term outlook is skewed downside. Investors should closely watch the 200-day moving average of $122.56 and the 30-day support of $145.03 as potential decision points for exits or entries. Sector leader Amgen is also under pressure (-2.74%), amplifying the need for sector-wide caution. Given the volatile technical environment, bearish options strategies and short-dated put positions present high-probability setups for capitalizing on the near-term selloff.